IXICO
Latest round
- Series A
Last raised
- Jul 2006
Total raised
- $1.7M
Investors
- 1
About IXICO
Based in the UK, IXICO Ltd., founded in 2004, operates out of London, UK, offering advanced services in neuroscience imaging.60 million, subsequently becoming publicly listed on the London Stock Exchange under the ticker "IXI". Founder Daniel Rueckert's entrepreneurial background has influenced IXICO's strategic direction, while CEO Giulio Cerroni leads ongoing operations.IXICO specializes in neuroscience imaging and biomarker analytics, offering a proprietary AI-driven platform designed to enhance the treatment of neurological disorders and streamline drug discovery processes. The IXICO Platform employs advanced, disease-specific algorithms to generate clinical data and insights that facilitate research and development decision-making, mitigate risks in clinical trials, and optimize drug development programs. The company's services cater to a diverse clientele, including leading pharmaceutical companies, innovative biotech firms, scientific consortia, and non-profit organizations focused on neurological diseases. IXICO's platform effectively manages and analyzes clinical trial data while providing precise imaging biomarker measurements related to conditions such as Alzheimer’s, Huntington’s, and Parkinson’s diseases.50. The company's revenue model is primarily structured around providing specialized services to clients in the biopharmaceutical sector. IXICO engages in direct business-to-business transactions, offering tailored solutions for neurological clinical trials, which may involve subscription-based partnerships or contractual agreements with pharmaceutical and biotech companies. Transactions typically encompass the provision of comprehensive data analytics, imaging biomarker assessments, and trial management services.300 mn to enhance its technological capabilities and expand its service offerings. The company aims to introduce new AI-driven products aimed specifically at improving imaging biomarker assessments by the end of 2024. Additionally, IXICO is targeting expansion into key markets in North America and Europe, planning to establish a significant presence there by 2025. The firm’s strategic investments will focus on developing partnerships with pharmaceutical companies in these regions to facilitate innovative clinical trial solutions.
Who invested in IXICO
1 investor across 1 round
See all investors in IXICO
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 25, 2006
Amount
$1.7M
Investors
Questions about IXICO
Who invested in IXICO?
IXICO has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has IXICO raised?
IXICO has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did IXICO last raise money?
IXICO's most recent round on record is a Series A, in Jul 2006.
What does IXICO do?
IXICO is a healthcare company.
Where is IXICO headquartered?
IXICO is headquartered in London, UK.
Which VCs invest in companies like IXICO?
Among active investors with capital left to deploy, Index Ventures, Forbion, Balderton Capital and Sofinnova Partners back healthcare companies at IXICO's stage. Their profiles are linked below.
VCs backing healthcare startups at Series A
Raising like IXICO? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.